Summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers added to standard medical therapy for treating stable ischemic heart disease

Journal of Managed Care Pharmacy

Volumn 17, Issue 5, 2011, Pages

  White, C Michael ^a   Greene, Laurence ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CILAZAPRIL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL; ZOFENOPRIL;

ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ARTICLE; BLOOD DYSCRASIA; COMPARATIVE EFFECTIVENESS; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG WITHDRAWAL; GOVERNMENT; HEALTH CARE PERSONNEL; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPOTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; MANAGED CARE; MORTALITY; OUTCOME ASSESSMENT; QUALITY OF LIFE; REVASCULARIZATION; RISK BENEFIT ANALYSIS; RISK REDUCTION; STROKE; SYNCOPE; SYSTEMATIC REVIEW; DRUG COMBINATION; HEART MUSCLE ISCHEMIA; REVIEW; UNITED STATES;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COMPARATIVE EFFECTIVENESS RESEARCH; DRUG THERAPY, COMBINATION; HUMANS; MYOCARDIAL ISCHEMIA; UNITED STATES; UNITED STATES AGENCY FOR HEALTHCARE RESEARCH AND QUALITY;

EID: 80052985345     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2011.17.s5.1     Document Type: Article

References (52)

1. American Heart Association Heart Disease and Stroke Statistics Writing Group. Heart disease and stroke statistics-2010 update. Circulation. 2010;121:1-170. Available at: http://circ.ahajournals.org/cgi/reprint/121/7/e46. Accessed February 25, 2011.
2. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina. J Am Coll Cardiol. 2002;41:159-68.
3. Rumsfeld JS. Managing patients with chronic angina: emerging therapeutic options for improving clinical efficacy and outcomes. J Manag Care Pharm. 2006;12(8 Suppl):S2-S3. Available at: http://www.amcp.org/data/jmcp/Oct_suppl06.pdf.
4. Mozaffarian D, Bryson CL, Spertus JA, et al. Anginal symptoms consistently predict total mortality among outpatients with coronary artery disease. Am Heart J. 2003;146:1015-22.
5. Heart Protection Study Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7-22.
6. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with aotrvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial. Lancet. 2003;361:1149-58.
7. Schmidt-Ott KM, Kagiyama S, Philips I. The multiple actions of angiotensin II in atherosclerosis. Regul Pept. 2000;93(1-3):65-77.
8. Faxon DP, Fuster V, Libby P, et al. Atherosclerotic vascular disease conference. Writing group III: pathophysiology. Circulation. 2004;109(21):2617-25. Available at: http://circ.ahajournals.org/cgi/reprint/109/21/2617. Accessed May 6, 2011.
9. Ambrosioni E, Borghi C, Magnani B, for the Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med. 1995;332(2):80-85. Available at: http://www.nejm.org/doi/full/10.1056/NEJM199501123320203. Accessed April 23, 2011.
10. Køber L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;333(25):1670-76. Available at: http://www.nejm.org/doi/full/10.1056/NEJM199512213332503. Accessed May 14, 2011.
11. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273(18):1450-56.
12. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial: the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355(9215):1582-87.
13. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667-75. Available at: http://www.nejm.org/doi/full/10.1056/NEJMoa010713. Accessed April 23, 2011.
14. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362(9386):759-66.
15. McMurray JJ, Ostergren J, Swedberg K, for the CHARM Investigators. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767-71.
16. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893-906. Available at: http://www.nejm.org/doi/full/10.1056/NEJMoa032292. Accessed April 23, 2011.
17. Fraker TD, Fihn SD, Gibbons RJ, et al. 2007 chronic angina focused update of the ACC/AHA 2002 Guidelines for the Management of Patients With Chronic Stable Angina. Circulation. 2007;116(23):2762-72.
18. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):1977-2016. Available at: http://circ.ahajournals.org/cgi/reprint/119/14/1977. Accessed February 25, 2011.
19. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American heart Association Task Force on Practice Guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure). Circulation. 2005;112:e154-e235. Available at: http://circ.ahajournals.org/cgi/reprint/112/12/e154. Accessed February 25, 2011.
20. Coleman CI, Baker WL, Kluger J, et al. Comparative effectiveness of angiotensin converting enzyme inhibitors or angiotensin II receptor blockers added to standard medical therapy for treating stable ischemic heart disease. Comparative effectiveness review number 1. Prepared for Agency for Healthcare Research and Quality. AHRQ publication no. 10-EHCOO2-EF. October 2009. Available at: http://www.effectivehealthcare.ahrq.gov/ehc/products/57/335/ischemic_finalRR1.pdf. Accessed April 7, 2011.
21. Agency for Healthcare Research and Quality. Methods guide for effectiveness and comparative effectiveness reviews. AHRQ publication no. 10(11)-EHC063-EF. March 2011. Available at: http://www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=318. Accessed April 23, 2011.
22. GRADE Working Group. http://www.gradeworkinggroup.org/. Accessed February 25, 2011.
23. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC192859/pdf/3270557.pdf. Accessed February 25, 2011.
24. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145-53. Available at: http://www.nejm.org/doi/full/10.1056/NEJM200001203420301. Accessed April 23, 2011.
25. MacMahon S, Sharpe N, Gamble G, et al. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. J Am Coll Cardiol. 2000;36(2):438-43.
26. Teo KK, Burton JR, Buller CE, et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation. 2000;102(15):1748-54. Available at: http://circ.ahajournals.org/cgi/reprint/102/15/1748. Accessed February 25, 2011.
27. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicenter trial (the EUROPA study). Lancet. 2003;362(9386):782-88.
28. Kondo J, Sone T, Tsuboi H, et al. Effects of low-dose angiotensin II receptor blocker Candesartan on cardiovascular events in patients with coronary artery disease. Am Heart J. 2003;146(6):e20. Available at: http://download.journals.elsevierhealth.com/pdfs/journals/0002-8703/PIIS0002870303004435.pdf. Accessed February 25, 2011.
29. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA. 2004;292(18):2217-26. Available at: http://jama.ama-assn.org/content/292/18/2217.full.pdf+html. Accessed February 25, 2011.
30. You U, Sumiyoshi T, Kodama K, et al. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: The Japan Multicenter Investigation for Cardiovascular diseases-B (JMIC-B) randomized trial. Hypertens Res. 2004;27(3):181-91. Available at: http://www.jstage.jst.go.jp/article/hypres/27/3/181/_pdf. Accessed February 25, 2011.
31. Braunwald E, Domanski MJ, Fowler SE, et al. The PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351(20):2058-68. Available at: http://www.nejm.org/doi/full/10.1056/NEJMoa042739. April 23, 2011.
32. Borhi C, Ambrosioni E, on behalf of the Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study Group. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA study. Am Heart J. 2007;153(3):e7-e14. Available at: http://download.journals.elsevierhealth.com/pdfs/journals/0002-8703/PIIS0002870306010623.pdf. Accessed February 25, 2011.
33. Yusuf S, Teo K, Anderson C, Pogue J, et al. The Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANCEND) Investigators. Effects of angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet. 2008;372(9644):1174-83.
34. Zonnad F, Kessler M, Lehert P, et al for the FOSIDIAL Investigators. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of Fosinopril and implications for future studies. Kidney Int. 2006;70(7):1318-24. Available at: http://www.nature.com/ki/journal/v70/n7/pdf/5001657a.pdf. Accessed February 25, 2011.
35. Takahashi A, Takase H, Toriyama T, et al. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis - a randomized study. Nephrol Dial Transplant. 2006;21(9):2507-12. Available at: http://ndt.oxfordjournals.org/content/21/9/2507.full.pdf+html. Accessed February 25, 2011.
36. Mann JFE, Yi QL, Sleight P, et al. on behalf of the HOPE Investigators. Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE study. Clin Nephrol. 2005;63(3):181-87.
37. Yusuf S, Teo KK, Pogue J, et al. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-59. Available at: http://www.nejm.org/doi/full/10.1056/NEJMoa0801317. Accessed May 14, 2011.
38. Faxon DP, for the Multicenter American Research trial with Cilazapril after Angioplasty to prevent Transluminal coronary Obstruction and Restenosis (MARCATOR) Study Group. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR study, a multicenter, double-blind, placebo-controlled trial of Cilazapril. J Am Coll Cardiol. 1995;25(2):362-69.
39. Kjoller-Hansen L, Steffensen R, Grande P. The Angiotensin-converting enzyme inhibitor Post REvascularization Study (APRES). J Am Coll Cardiol. 2000;35(4):881-88.
40. Kondo J, Sone T, Tsuboi H, et al. Effect of quinapril on intimal hyperplasia after coronary stenting as assessed by intravascular ultrasound. Am J Cardiol. 2001;87(4):443-45.
41. Meurice T, Bauters C, Hermant X, et al. Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): a randomized, double-blind, placebo-controlled trial. Lancet. 2001;357(9265):1321-24.
42. Pitt B, O'Neill B, Feldman R, et al. The Quinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol. 2001;87(9):1058-63.
43. Radke PW, Figulla HR, Drexler H, et al for the AACHEN Trial Investigators. A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker Candesartan cilexetil on intimal hyperplasia after coronary stent implantation. Am Heart J. 2006;152(4):e1-e6.
44. Fouleau JL, Warnica WJ, Baillot R, et al. for the IMAGINE (Ischemia Management with Accupril post-bypass Graft via Inhibition of the coNverting Enzyme) Investigators. Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery. Circulation. 2008;117(1):24-31. Available at: http://circ.ahajournals.org/cgi/reprint/117/1/24. Accessed February 25, 2011.
45. Solomon SD, Rice MM, Jablonski KA, et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation. 2006;114(1):26-31. Available at: http://circ.ahajournals.org/cgi/reprint/114/1/26. Accessed February 25, 2011.
46. Brugts JJ, Boersma E, Chonchol M, et al. on behalf of the EUROPA Investigators. The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency. J Am Coll Cardiol. 2007;50(22):2148-55.
47. Mann JFE, Gerstein HC, Pogue J, et al. for the HOPE Investigators. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134(8):629-36. Available at: http://www.annals.org/content/134/8/629.full.pdf+html. Accessed February 25, 2011.
48. Dagenais GR, Pogue J, Fox K, et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet. 2006;368(9535):581-88.
49. White CM. Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors. Pharmacotherapy. 1998;18(3):588-99.
50. Song JC, White CM. Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24.
51. Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials. Lancet Oncol. 2011;12(1):65-82. Epub 2010 Nov 29.
52. Baker WL, Coleman CI, Kluger J, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease. Ann Intern Med. 2009;151(12):861-71.